EUCTR2010-021377-36-DE进行中（未招募）1 期
A two stage phase III, international, multi center, randomized, controlled, open-label study to investigate the pharmacokinetics, efficacy and safety of rituximab SC in combination with CHOP or CVP versus rituximab IV in combination with CHOP or CVP in patients with previously untreated follicular lymphoma followed by maintenance treatment with either rituximab SC or rituximab IV. - SABRINA
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 530
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Written informed consent and ability and willingness to comply with the visit schedule and assessments required by the protocol
- •2. Age = 18 years
- •3. Histologically confirmed CD20-positive, follicular NHL grade 1, 2 or 3a, according to the WHO classification system. A tumor biopsy (lymph node, bone marrow, etc.) must have been performed within 6 months prior to screening with material available for central review.
- •4. No prior treatment. (Note that patients diagnosed in the past who had been on watch and wait” can enter the trial if a tumor biopsy obtained within the last 6 months is available for central review)
- •5. Patients with at least one of the following signs and symptoms requiring treatment:
- •a) Bulky disease defined as a nodal or extranodal (except spleen) mass = 7 cm in its greatest diameter
- •b) B-symptoms
- •c) Elevated serum LDH or ß2-microglobulin
- •d) Involvement of at least 3 nodal sites (each with a diameter greater than 3 cm)
- •e) Symptomatic spleen enlargement
- •f) Compressive syndrome
- •g) Pleura/peritoneal effusion
- •6. ECOG performance status of 0-2
- •7. Life expectancy of 6 months or more
- •8. Bi-dimensionally measurable disease (measurable by CT or MRI)
- •9. A negative serum pregnancy test 1 week prior to treatment must be available both for pre-menopausal women and for women who are less than 2 years after the onset of menopause, or within 14 days with a confirmatory urine pregnancy test within 1 week prior to study treatment start
- •10. Adequate hematological function within 28 days prior to randomization (unless related to lymphoma infiltration of the bone marrow):
- •a) Hemoglobin (Hb) = 8.0 g/dL (5 mmol/L)
- •b) Absolute neutrophil count (ANC) = 1.5 x 10exp9/L
- •c) Platelet count = 100 x 10exp9/L
- •Are the trial subjects under 18? no
- •Number of subjects for this age range: 0
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 420
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 110
排除标准
- •1. Grade 3b follicular lymphoma
- •2. Transformation to high-grade lymphoma secondary to follicular lymphoma
- •3. Types of NHL other than follicular lymphoma according to the WHO classification
- •4. Presence or history of CNS disease (CNS lymphoma or lymphomatous meningitis)
- •5. Corticoid therapy during the last 4 weeks, unless the dose was below 20 mg/day prednisone equivalent
- •6. Presence or history of malignancies other than follicular lymphoma. (Patients with a history of curatively treated basal or squamous cell carcinoma of the skin, or in situ carcinoma of the cervix are generally eligible. Any other cancer for which the patient has been in complete remission for at least 5 years are generally eligible)
- •7. Major surgery within 28 days prior to study entry (lymph node biopsy is not regarded to be a major surgery)
- •8. Pregnancy or nursing females
- •9. Fertile men or women of childbearing potential unless they agree to use effective contraception throughout the study and for at least 12 months after the last dose of rituximab
- •10. Any of the following abnormal laboratory values:
- •a) Serum creatinine >2 mg/dL (197 µmol/L)
- •b) Total bilirubin >1.5 times the upper limit of normal
- •c) Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) >2.5 times the upper limit of normal (or >5 times the upper limit of normal in the presence of liver involvement)
- •11. Active HBV or HCV infection or history of HBV infection (patients with serological evidence of current or past HBV exposure are excluded unless the serological findings are clearly due to vaccination)
- •12. Known HIV infection
- •13. Known active bacterial, viral, fungal or mycobacterial, or any major episode of infections requiring hospitalization or treatment with IV antibiotics within 4 weeks of start of study medication, or oral antibiotics within 2 weeks prior to start of study medication
- •14. History of organ transplantation including hematological stem cell transplantation
- •15. Uncontrolled concomitant diseases which could affect compliance with the protocol or interpretation of results, including significant cardiovascular disease (such as New York Heart Association class III or IV cardiac disease, myocardial infarction within the last 6 months, unstable arrhythmias, or unstable angina) or pulmonary disease (including obstructive pulmonary disease and history of symptomatic bronchospasm)
- •16. Known hypersensitivity to murine products or any other study drugs or its ingredients
- •17. Current or recent treatment with another investigational drug or participation in another interventional clinical study within the 30 days prior study entry
- •18. Any other medical or psychological condition that contraindicates use of an investigational drug, that would preclude adequate collection of study data, or that would compromise the patient’s ability to give informed consent.
研究者
相似试验
进行中（未招募）
1 期
A Study of MabThera (Rituximab) Subcutaneous Vs. MabThera (Rituximab) Intravenous in Patients With Follicular Non-Hodgkin's Lymphoma.EUCTR2010-021377-36-GBF. Hoffmann-La Roche Ltd410
进行中（未招募）
1 期
A two stage phase III, international, multi center, randomized, controlled, open-label study to investigate the pharmacokinetics, efficacy and safety of rituximab SC in combination with CHOP or CVP versus rituximab IV in combination with CHOP or CVP in patients with previously untreated follicular lymphoma followed by maintenance treatment with either rituximab SC or rituximab IV. - SABRINAPreviously untreated, CD20-positive follicular lymphoma (FL) grade 1-2, 3aMedDRA version: 18.0Level: LLTClassification code 10067070Term: Follicular B-cell non-Hodgkin's lymphomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 18.0Level: PTClassification code 10061170Term: Follicle centre lymphoma, follicular grade I, II, IIISystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2010-021377-36-FIF. Hoffmann-La Roche Ltd530
进行中（未招募）
1 期
A Study of MabThera (Rituximab) Subcutaneous Vs. MabThera (Rituximab) Intravenous in Patients With Follicular Non-Hodgkin's Lymphoma.EUCTR2010-021377-36-FRF. Hoffmann-La Roche Ltd530
进行中（未招募）
1 期
A Study of MabThera (Rituximab) Subcutaneous Vs. MabThera (Rituximab) Intravenous in Patients With Follicular Non-Hodgkin's Lymphoma.EUCTR2010-021377-36-BGF. Hoffmann-La Roche Ltd530
进行中（未招募）
1 期
A Study of MabThera (Rituximab) Subcutaneous Vs. MabThera (Rituximab) Intravenous in Patients With Follicular Non-Hodgkin's Lymphoma.Previously untreated, CD20-positive follicular lymphoma (FL) grade 1-2, 3aMedDRA version: 17.1Level: LLTClassification code 10067070Term: Follicular B-cell non-Hodgkin's lymphomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 17.1Level: PTClassification code 10061170Term: Follicle centre lymphoma, follicular grade I, II, IIISystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2010-021377-36-BEF. Hoffmann-La Roche Ltd530